These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22453559)

  • 1. Birth cohort screening may help find hepatitis C cases.
    Voelker R
    JAMA; 2012 Mar; 307(12):1242. PubMed ID: 22453559
    [No Abstract]   [Full Text] [Related]  

  • 2. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges?
    Vogel M; Page E; Nelson M; Rockstroh JK
    J HIV Ther; 2009 Mar; 14(1):8-12. PubMed ID: 19731559
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin.
    Sperati CJ
    Clin Nephrol; 2013 Sep; 80(3):231-4. PubMed ID: 22541681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
    Bartlett JG
    Hopkins HIV Rep; 2005 May; 17(3):15. PubMed ID: 16419314
    [No Abstract]   [Full Text] [Related]  

  • 12. [Protocol for the antiviral therapy of hepatitis C].
    Judit G; Gábor H; Béla H; Mihály M; Alajos P; Ferenc S; István T; László T; ;
    Orv Hetil; 2010 Jan; 151(2):66-72. PubMed ID: 20061235
    [No Abstract]   [Full Text] [Related]  

  • 13. Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.
    Chen TM; Tung JN
    Am J Gastroenterol; 2009 Aug; 104(8):2117-9. PubMed ID: 19661945
    [No Abstract]   [Full Text] [Related]  

  • 14. Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    de Mattos AZ; de Almeida PR; Tovo CV; de Mattos AA
    Hepatology; 2010 Nov; 52(5):1867. PubMed ID: 20726033
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 18. Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?
    Roche B; Samuel D
    J Hepatol; 2010 May; 52(5):630-2. PubMed ID: 20334948
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis drug gets approval for coinfection treatment.
    AIDS Patient Care STDS; 2005 May; 19(5):351. PubMed ID: 15916498
    [No Abstract]   [Full Text] [Related]  

  • 20. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
    Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
    Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.